2022 ESMO大会即将于9月9日（欧洲中部夏令时间，CEST）在法国首都巴黎凡尔赛门展览馆开幕，「肿瘤资讯」整理了会上将进行报告的乳腺癌相关口头报告研究，供您参考。
Proffered Paper session
纳武利尤单抗和伊匹木单抗治疗具有肿瘤浸润淋巴细胞的早期三阴性乳腺癌：BELLINI试验的首次结果
摘要号：LBA13
原标题：Nivolumab and ipilimumab in early stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): first results from the BELLINI trial
报告专家：Iris Nederlof (Amsterdam, Netherlands)
年龄、复发评分和卵巢功能抑制对术前短期内分泌治疗效果的影响：ADAPT和 ADAPTcycle 试验分析
摘要号：LBA14
原标题：Impact of age, Recurrence Score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials
报告专家：Oleg Gluz (Mönchengladbach, Germany)
MONARCH 3：在HR+/HER2- 晚期乳腺癌患者中联合阿贝西利和非甾体类芳香化酶抑制剂治疗的中期总生存期结果
摘要号：LBA15
原标题：MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)
报告专家：Matthew P. Goetz (Rochester, United States of America)
达尔西利联合来曲唑或阿那曲唑一线治疗HR+/HER2-晚期乳腺癌 (DAWNA-2)：一项 III 期试验
摘要号：LBA16
原标题：Dalpiciclib plus letrozole or anastrozole as 1st-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): a phase 3 trial
报告专家：徐兵河 (北京, 中国)
一线化疗-免疫治疗的随机II期SYNERGY试验的主要终点结果：采用度伐利尤单抗、紫杉醇和卡铂联合或不联合抗CD73抗体oleclumab治疗晚期或转移性三阴性乳腺癌
摘要号：LBA17
原标题：Primary endpoint results of SYNERGY, a randomized phase 2 trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)
报告专家：Laurence Buisseret (Brussels, Belgium)
III期TROPiCS-02研究：在HR+/HER2-转移性乳腺癌患者中比较戈沙妥珠单抗与医生选择性治疗的总生存期结果
摘要号：LBA76
原标题：Overall survival (OS) results from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)
报告专家：Hope S. Rugo (San Francisco, United States of America)
突变特征分析揭示ER+/HER2-转移性乳腺癌中与内分泌治疗或CDK4/6i耐药相关的基因组不稳定模式
摘要号：210O
原标题：Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)
报告专家：Antonio Marra (New York, United States of America)
随机III期DESTINY-Breast04临床试验患者报告结局：在HER2低表达转移性乳腺癌患者中比较T-DXd与医生选择的治疗
摘要号：217O
原标题：Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan
(T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC）报告专家：Naoto T. Ueno (Houston, United States of America)
序贯内分泌辅助治疗后延长芳香化酶抑制剂治疗：III期DATA试验的最终结果
摘要号：133O
原标题：Extended Adjuvant Aromatase Inhibition After Sequential Endocrine Therapy: final results of the phase 3 DATA trial
报告专家：Vivianne C. Tjan-Heijnen (Maastricht, Netherlands)
早期乳腺癌患者的剂量密集辅助化疗：随机、III期Gruppo Italiano Mammella(GIM)研究的最终结果
摘要号：134O
原标题：Dose-dense adjuvant chemotherapy in early-stage breast cancer patients : end-of-study results from a randomised, phase 3 trial of the Gruppo Italiano Mammella (GIM)
报告专家：Lucia Del Mastro (Genova, Italy)
Mini Oral session
在HR+/HER2+ 晚期乳腺癌患者中比较阿贝西利+ 曲妥珠单抗 +/-氟维司群与曲妥珠单抗 + 化疗的最终总生存期 (monarcHER) ：一项随机、开放标签的II期试验
摘要号：LBA18
原标题：Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): a randomized, open-label, phase 2 trial
报告专家：Fabrice André (Villejuif, France)
吡咯替尼或安慰剂联合曲妥珠单抗和多西他赛治疗 HER2+转移性乳腺癌 (PHILA)：一项随机 III 期试验
摘要号：LBA19
原标题：Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): a randomized phase 3 trial
报告专家：徐兵河(北京, 中国)
一项在ER+/HER2-、出现雌激素受体1突变、经过芳香化酶和CDK4/6抑制剂治疗后疾病进展的局部晚期/转移性乳腺癌患者比较lasofoxifene与氟维司群的开放标签的随机化研究
摘要号：LBA20
原标题：Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors
报告专家：Matthew P. Goetz (Rochester, United States of America)
Giredestrant (GDC-9545)与医生选择的内分泌单药治疗在ER+/HER2-局部晚期/转移性乳腺癌患者中的比较: II期，随机，开放标签acelERA BC研究的初步分析
摘要号：211MO
原标题：Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase 2, randomised, open-label acelERA BC study
报告专家：Miguel Martin Jimenez (Madrid, Spain)
II期AMEERA-3试验：在内分泌耐药ER+/ HER2− 晚期乳腺癌患者中对比amcenestrant单药与医生选择的内分泌治疗
摘要号：212MO
原标题：AMEERA-3, a Phase 2 study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC)
报告专家：Sara M. Tolaney (Boston, MA, United States of America)
达罗他胺或卡培他滨治疗三阴性雄激素受体阳性晚期乳腺癌的主要终点分析(UCBG3-06 START随机II期试验)
摘要号：213MO
原标题：Primary endpoint analysis of a randomized phase 2 of darolutamide or capecitabine in patients with triple-negative androgen receptor positive advanced breast cancer (UCBG3-06 START trial)
报告专家：Monica Arnedos (Bordeaux, France)
在 III 期 TROPiCS-02 研究中，戈沙妥珠单抗对由HER2免疫组化诊断的HR+/HER2-转移性乳腺癌的疗效
摘要号：214MO
原标题：Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase 3 TROPiCS-02 study
报告专家：Peter Schmid (London, United Kingdom)
ICON：一项随机IIb期研究，评估化疗联合伊匹木单抗和纳武利尤单抗治疗转移性激素受体阳性乳腺癌
摘要号：215MO
原标题：ICON – a randomized phase IIb study evaluating chemotherapy combined with ipilimumab and nivolumab in metastatic hormone receptor positive breast cancer
报告专家：Jon Amund Kyte (Oslo, Norway)
口服长春瑞滨+环磷酰胺和卡培他滨节拍化疗 vs 每周紫杉醇作为ER+/HER2-转移性乳腺癌患者的一线或二线治疗的随机II期试验:METEORA-II试验(IBCSG 54-16)
摘要号：216MO
原标题：A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): the METEORA-II trial (IBCSG 54-16)
报告专家：Elisabetta Munzone (Milan, Italy)
KEYNOTE-522的HRQoL结果：新辅助帕博利珠单抗联合化疗+辅助帕博利珠单抗vs 安慰剂联合化疗+安慰剂治疗早期TNBC
摘要号：135MO
原标题：HRQoL With Neoadjuvant Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy, Followed by Adjuvant Pembrolizumab vs Placebo for Early-Stage TNBC: Results From KEYNOTE-522
报告专家：Rebecca A. Dent (Singapore, Singapore)
在IBCSG 22-00研究中，低剂量环磷酰胺和甲氨蝶呤维持性化疗在TNBC亚型中的差异性益处
摘要号：136MO
原标题：Differential benefit of low-dose cyclophosphamide and methotrexate maintenance chemotherapy among TNBC subtypes in the context of the IBCSG 22-00 study
报告专家：Andrea Joaquin Garcia (Brussels, Belgium)
术前局部麻醉对早期乳腺癌肿瘤周围浸润的影响
摘要号：137MO
原标题：Effect of peri-tumoral infiltration of local anaesthetic prior to surgery on survival in early breast cancer
报告专家：Rajendra Badwe (Mumbai, India)
TEAM试验中，乳腺癌指数在绝经后的早期HR+乳腺癌妇女中的预后预测表现
摘要号：138MO
原标题：Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial
报告专家：John M. Bartlett (Edinburgh, United Kingdom)
在ALTTO试验中，确定与辅助曲妥珠单抗治疗后的预后有关的生物学驱动的HER2阳性乳腺癌亚组
摘要号：139MO
原标题：Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial
报告专家：Mattia Rediti (Brussels, Belgium)
新辅助曲妥珠单抗和帕妥珠单抗治疗的HER2+/HR+乳腺癌的HER2DX基因组检测：PerELISA试验的相关分析
摘要号：140MO
原标题：HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA trial
报告专家：Valentina Guarneri (Padova, Italy)
接受新辅助卡铂+多西他赛治疗的可手术三阴性乳腺癌根据TNBCtype4分类的病理缓解和早期生存数据
摘要号：141MO
原标题：Pathological response and early survival data according to TNBCtype4 classifier in operable triple negative breast cancer (TNBC) treated with neoadjuvant carboplatin and docetaxel
报告专家：Isabel Echavarria Diaz-Guardamino (Madrid, Spain)
排版编辑：肿瘤资讯-Paine
苏公网安备32059002004080号
